Want to see IN:ACUTAAS full AI Analyst Report?
Top Page
Acutaas Chemicals
(ACUTAAS)
Select Model
Select Model
Rating:68Neutral
Price Target:
₹3,451.00
▲(97.52% Upside)
Action:Downgraded
Date:06/30/26
The score is primarily supported by strong FY2026 operating performance and a conservatively leveraged balance sheet. It is held back by weak cash conversion (negative free cash flow) and a demanding valuation (high P/E). Technical scoring is limited due to missing indicator data.
Positive Factors
Strong Revenue and Profit Growth
The sharp FY2026 revenue acceleration, combined with materially higher net and EBIT margins, indicates strong demand and improved operating leverage. If this performance persists, it can expand the company’s earnings base and provide resources for continued investment and competitive development.
Negative Factors
Persistently Negative Free Cash Flow
Despite stronger operating cash flow, recurring negative free cash flow indicates that reinvestment and/or working-capital demands continue to absorb cash. Sustained cash outflows could constrain internally funded expansion and make future growth more dependent on disciplined capital allocation.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue and Profit Growth
The sharp FY2026 revenue acceleration, combined with materially higher net and EBIT margins, indicates strong demand and improved operating leverage. If this performance persists, it can expand the company’s earnings base and provide resources for continued investment and competitive development.
Read all positive factors
Acutaas Chemicals (ACUTAAS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹259.23B
Dividend Yield0.05%
Average Volume (3M)30.00K
Price to Earnings (P/E)67.2
Beta (1Y)1.41
Revenue Growth40.90%
EPS Growth104.27%
CountryIN
Employees1,007
SectorGeneral
Sector StrengthN/A
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)33.38
Shares Outstanding81,871,124
10 Day Avg. Volume41,202
30 Day Avg. Volume29,998
Financial Highlights & Ratios
PEG Ratio0.91
Price to Book (P/B)7.73
Price to Sales (P/S)10.06
P/FCF Ratio-132.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹3,773.00Price Target Upside115.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)56.08
Revenue Forecast (FY)₹17.92B
Acutaas Chemicals Business Overview & Revenue Model
Company Description
Based in Surat, India, Acutaas Chemicals Limited, founded in 2004, is engaged in the development, production, and global distribution of pharmaceutical intermediates. These crucial compounds are utilized in both regulated and generic active pharma...
Acutaas Chemicals Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
88
Very Positive
Cash Flow
54
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.97B | 10.07B | 6.17B | 5.18B | 3.41B | 2.40B |
| Gross Profit | 5.17B | 4.55B | 2.86B | 1.94B | 1.22B | 776.58M |
| EBITDA | 2.99B | 2.32B | 1.27B | 1.08B | 811.14M | 438.14M |
| Net Income | 2.24B | 1.59B | 832.90M | 719.46M | 539.99M | 274.70M |
Balance Sheet | ||||||
| Total Assets | 16.96B | 15.49B | 7.67B | 6.59B | 4.13B | 2.32B |
| Cash, Cash Equivalents and Short-Term Investments | 2.41B | 2.49B | 586.70M | 615.46M | 26.85M | 38.22M |
| Total Debt | 83.49M | 129.39M | 36.00M | 8.44M | 1.37B | 594.20M |
| Total Liabilities | 2.57B | 2.29B | 1.73B | 1.37B | 2.46B | 1.20B |
| Stockholders Equity | 14.14B | 13.10B | 5.94B | 5.22B | 1.67B | 1.12B |
Cash Flow | ||||||
| Free Cash Flow | -46.49M | -763.00M | -308.73M | -424.18M | -794.33M | 54.71M |
| Operating Cash Flow | 1.37B | 1.18B | 655.30M | -86.60M | 271.45M | 270.77M |
| Investing Cash Flow | -1.40B | -2.24B | -330.44M | -1.24B | -1.00B | -239.44M |
| Financing Cash Flow | -91.38M | 2.61B | -122.50M | 1.40B | 721.08M | 1.94M |
Acutaas Chemicals Technical Analysis
Neutral
1747.20
Price Trends
3343.98
Negative
3116.54
Positive
2530.51
Positive
Market Momentum
-31.73
Positive
46.52
Neutral
23.71
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ACUTAAS, the sentiment is Neutral. The current price of 1747.2 is below the 20-day moving average (MA) of 3215.54, below the 50-day MA of 3343.98, and below the 200-day MA of 2530.51, indicating a neutral trend. The MACD of -31.73 indicates Positive momentum. The RSI at 46.52 is Neutral, neither overbought nor oversold. The STOCH value of 23.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:ACUTAAS.
Acutaas Chemicals Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ₹187.93B | 23.60 | ― | 0.48% | 15.75% | 59.22% | |
73 Outperform | ₹135.83B | 30.26 | ― | 0.58% | 5.09% | 5.44% | |
68 Neutral | ₹259.23B | 67.18 | ― | 0.05% | 40.90% | 104.27% | |
59 Neutral | ₹215.88B | 91.45 | ― | ― | 33.79% | 34.24% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | ₹141.02B | 80.23 | ― | 0.12% | 51.77% | 36.94% | |
45 Neutral | ₹178.43B | 33.67 | ― | 0.20% | 27.05% | 123.98% |
* General Sector Average
IN:ACUTAAS
Acutaas Chemicals
3,180.90
1,677.93
111.64%
IN:AARTIIND
AARTI Industries Ltd
503.75
115.45
29.73%
IN:AETHER
Aether Industries Ltd.
1,643.35
902.80
121.91%
IN:ANURAS
Anupam Rasayan India Ltd.
1,237.25
155.40
14.36%
IN:ATUL
Atul Limited
6,312.05
-10.24
-0.16%
IN:VINATIORGA
Vinati Organics Limited
1,345.25
-371.08
-21.62%
Acutaas Chemicals Corporate Events
Acutaas Chemicals Sets Record Date for 50% Final Dividend
Aug 29, 2026
Acutaas Chemicals Limited has set 17 September 2026 as the record date to determine shareholders eligible to receive a proposed final dividend for the financial year 2025-26. The company plans a payout of Rs. 2.50 per fully paid equity share of fa...
Acutaas Chemicals Outlines TDS Rules on Proposed FY26 Final Dividend
Aug 29, 2026
Acutaas Chemicals has informed shareholders that its board has recommended a final dividend of Rs 2.50 per equity share with a face value of Re 5 for FY 2025-26, subject to approval at the 19th Annual General Meeting on 24 September 2026. The divi...
Acutaas opens South Korean semiconductor materials plant via Indichem
Aug 28, 2026
Acutaas Chemicals has inaugurated a semiconductor materials plant in Gongju, South Korea, via its step-down subsidiary Indichem Inc., completing the state-of-the-art facility just eleven months after groundbreaking. The plant sits on a 16,513.7 sq...
Acutaas Chemicals Publishes AGM Notice to Meet SEBI Disclosure Rules
Aug 24, 2026
Acutaas Chemicals Limited has notified exchanges that it has published newspaper advertisements regarding its 19th Annual General Meeting, scheduled for September 24, 2026 at 11:30 a.m. IST. The notices appeared in the Financial Express All India ...
Acutaas Chemicals Publishes Q1 FY26 Investor Presentation
Jul 24, 2026
Acutaas Chemicals Limited has released an investor presentation detailing its financial results for the first quarter ended June 30, 2026 and key business updates. The document, prepared in line with SEBI disclosure norms, is available on the comp...
Tax Authority Conducts Search at Acutaas Chemicals’ Surat Facilities
Jun 22, 2026
Acutaas Chemicals disclosed that the Central Goods Service Tax and Central Excise Anti-evasion Department in Surat initiated an inspection and search at its registered office and Sachin manufacturing unit under Section 67(2) of the Central Goods ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.